Gooderham, Melinda http://orcid.org/0000-0001-8926-0113
Vender, Ronald
Crowley, Jeffrey
Hong, H. Chih-Ho
Feely, Meghan
Garrelts, Alyssa
See, Kyoungah
Konicek, Bruce
Green, Lawrence
Clinical trials referenced in this document:
Documents that mention this clinical trial
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)
https://doi.org/10.1007/s13555-023-01075-y
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s40744-023-00553-1
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
https://doi.org/10.1007/s13555-022-00704-2
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 11 September 2023
Accepted: 14 November 2023
First Online: 9 February 2024
Declarations
:
: Melissa Gooderham has received honoraria, grants, and/or research funding as a speaker, investigator, advisory board member, data safety monitoring board member, and/or consultant for AbbVie, Amgen, Arcutis, Aristea, AnaptysBio, Apogee, Bausch Health, Boehringer Ingelheim, Dermira, Dermavant, Eli Lilly and Company, Galderma, GlaxoSmithKline, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Meiji, Moonlake, Novartis, Nimbus, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda, Tarsus, UCB Pharma, Union, and Ventyx. Ron Vender has received grants, research support, speakers bureau funding, honoraria, and/or consulting fees from AbbVie, Actelion, Amgen, Aralez Bio, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Cipher Pharmaceuticals, Dermavant Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Janssen, KabiCare, LEO Pharma, Meiji Seika Pharma, Merck, Nimbus Therapeutics, Novartis, Paladin Labs, Pfizer, Regeneron, Sandoz, Sun Pharma, Takeda, UCB Pharma, and Viatris-Mylan. Jeffrey Crowley has received honoraria as a speaker and/or served as a consultant for AbbVie, Amgen, Arcutis, BMS, Eli Lilly and Company, Janssen, Novartis, Pfizer, Regeneron, Sanofi-Aventis, and Sun Pharma, and is an owner and employee of Bakersfield Dermatology, which has received grant and/or research support from AbbVie, Amgen, BMS, Celgene, Eli Lilly and Company, Janssen, Novartis, and Pfizer; he also serves on the Data Safety Monitoring Board for Cara Pharmaceuticals and Alumis. H. Chih-Ho Hong has been a speaker, investigator, advisory board member, and/or consultant for AbbVie, Amgen, Arcutis, Avillion, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cutanea, Dermavant, Dermira, DS Biopharma, Eli Lilly and Company, Evelo Biosciences, Galderma, GlaxoSmithKline, Incyte Corp., Janssen, LEO Pharma, MedImmune, Merck, Mirimar, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Regeneron, Roche, and UCB Pharma. Meghan Feely is associate staff at Mount Sinai Hospital and has received grants and/or consulting fees from Aerolase, Castle Biosciences, CeraVe-L’Oréal, Galderma, Glow Recipe, La Roche-Posay-L’Oréal, Revian, Sonoma Pharmaceuticals, Sun Pharma, and Suneva Medical. Meghan Feely, Alyssa Garrelts, Kyoungah See, and Bruce Konicek are employees and shareholders of Eli Lilly and Company. Lawrence Green is an investigator, speaker, and/or consultant for AbbVie, Amgen, Arcutis, Dermavant, Eli Lilly and Company, Janssen, MC2 Therapeutics, Ortho Dermatologics, Sun Pharma, and UCB Pharma.
: The study protocol was approved by local ethics review boards (Table InternalRef removed) and was conducted according to the International Conference on Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki. All patients were required to give informed consent for participation in the study.